Therapeutic Response

v::NRG1 status confers therapeutic sensitivity to Zenocutuzumab in patients with Cholangiocarcinoma.

Statements

Source and description
Bizengri (zenocutuzumab-zbco) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to zenocutuzumab for the treatment of adults with advanced unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.